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Abstract: Cell-based tendon therapies with tenocytes as a cell source need effective tenocyte in vitro
expansion before application for tendinopathies and tendon injuries. Supplementation of tenocyte
culture with biomolecules that can boost proliferation and matrix synthesis is one viable option
for supporting cell expansion. In this in vitro study, the impacts of ascorbic acid or PDGF-BB
supplementation on rabbit Achilles tenocyte culture were studied. Namely, cell proliferation, changes
in gene expression of several ECM and tendon markers (collagen I, collagen III, fibronectin, aggrecan,
biglycan, decorin, ki67, tenascin-C, tenomodulin, Mohawk, α-SMA, MMP-2, MMP-9, TIMP1, and
TIMP2) and ECM deposition (collagen I and fibronectin) were assessed. Ascorbic acid and PDGF-BB
enhanced tenocyte proliferation, while ascorbic acid significantly accelerated the deposition of collagen
I. Both biomolecules led to different changes in the gene expression profile of the cultured tenocytes,
where upregulation of collagen I, Mohawk, decorin, MMP-2, and TIMP-2 was observed with ascorbic
acid, while these markers were downregulated by PDGF-BB supplementation. Vice versa, there was
an upregulation of fibronectin, biglycan and tenascin-C by PDGF-BB supplementation, while ascorbic
acid led to a downregulation of these markers. However, both biomolecules are promising candidates
for improving and accelerating the in vitro expansion of tenocytes, which is vital for various tendon
tissue engineering approaches or cell-based tendon therapy.
Keywords: tenocytes; PDGF-BB; ascorbic acid; proliferation; gene expression; collagen I; fibronectin
1. Introduction
Different cell-based therapies, including biological and decellularized tissues [1,2], cell-seeded
grafts from natural and synthetic biomaterials [3,4] or stem cell-based approaches [5] have been
explored for the treatment of tendinopathies and tendon injuries. Among them, there are several
reports on the use of mesenchymal stem cells (MSCs) for tendon cell-based therapy [6,7], or as a cell
source for tissue engineered grafts and constructs where tenogenic differentiation was studied [8,9].
On the other hand, there are fewer reports exploring tenocytes for cell-based therapy [1,10,11], which
might be due to the scarcity of donor tendons or loss of phenotype during in vitro expansion [12].
However, several studies describe the positive effects of autologous human tenocyte transplantation
on tendon healing [13–15]. This suggests the need for tenocyte expansion and optimization of the
expansion protocols before application, addressing increased proliferation, matrix synthesis, and
phenotype retention in order to make them suitable for cell therapy. While the application of stem
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cells and cues for tenogenic differentiation have been reported extensively [16–19], the use of tenocytes
to treat tendon diseases is currently not investigated widely. This may be due to two facts: first,
tenocytes occur in relatively low numbers in tendon tissue and have to be expanded in vitro prior
to application; second, tenocytes may undergo a phenotypic drift in culture, losing typical tendon
markers during passaging, and consequently providing a limited range of low passages convenient for
cellular therapy [20]. In comparison to stem cells, tenocytes are the main cell component of the tendon
tissue. They are fully differentiated and functional within the tendon connective tissue [21], and can be
easily extracted from parts of tendon tissue, although donor-site morbidity has to be taken into account.
Nevertheless, tenocytes present an attractive cell source for tendon tissue engineering applications.
One way to improve cell-based tendon therapy is to perform a pre-treatment on the cell culture
in order to increase cell proliferation and matrix synthesis before an application. Strategies for
pre-treatment of tenocyte or MSCs cell culture include mechanical stimulation [8,22], three-dimensional
spheroid cultures [23], macromolecular crowding [24] or biochemical supplementation of the culture
medium [12,25]. From biochemical supplementation, stimulation by different growth factors, including
transforming growth factor-beta (TGF-β) [8], bone morphogenetic protein-12 (BMP-12) [26], connective
tissue growth factor (CTGF) [27], and platelet-derived growth factor-BB (PDGF-BB) [28] has been
explored. Small bioactive molecules like ascorbic acid (AA), i.e., Vitamin C [29–31] or glutamine [12]
have also been investigated. Interestingly, bioactive molecules are often investigated concerning
their effect on stem cell tenogenic differentiation under serum+ conditions [18,32–34] and serum-free
conditions [35,36], while effects on tenocytes have not been investigated in-depth so far, and only
few reports for human or animal tenocytes exist [37–39]. Additionally, it is beneficial to determine
the effects of biomolecules on tenocyte culture not only for pre-treatment for cell-based therapy but
also since tenocytes are the main cell population affected by the delivery of drugs explored for aiding
tendon tissue healing and repair.
Taking this into account, we investigated the effects of two biomolecules on rabbit Achilles tenocyte
culture in vitro; namely PDGF-BB and AA. PDGF-BB is well known for its mitogenic, chemotactic and
angiogenic properties and has been explored as a growth factor to help the tendon healing process
upon injury or rupture [28]. In addition, PDGF-BB also has an important role in stimulating the
production of other growth factors, such as insulin-like growth factor (IGF-1), that in turn can also
support tendon healing [40]. In contrast, TGF-β may lead to aberrant scar formation [41–43], while
BMPs are reported to turn stem cell towards tenogenic lineage, but less to boost matrix formation.
However, the PDGF-BB effects on tenocyte matrix synthesis or gene expression over time have not
been investigated in detail so far.
On the other hand, AA is known to promote collagen biosynthesis [44,45], and it has also been
suggested as a molecule that could help tendons to heal [46]. While its effects on matrix synthesis
are known to some extent [30], what changes its supplementation might bring to the phenotype of
tenocytes is less known.
Hence, the hypotheses in this study were:
a. PDGF-BB and AA increase the proliferation of tenocytes.
b. PDGF-BB and AA enhance extracellular matrix synthesis.
c. PDGF-BB and AA change the gene expression of tendon markers.
d. PDGF-BB and AA released from bioactive scaffolds support tenocyte growth and ECM synthesis.
2. Results
2.1. AA and PDGF-BB Supplementation Increase Tenocyte Proliferation
In order to assess the effect of both biomolecules on cell culture proliferation, tenocytes cultured in
both serum+ and serum-free medium were supplemented with different concentrations of PDGF-BB
and AA. Cell proliferation was evaluated by the EdU assay, and data for AA treatment is shown in
Figure 1. Data for the PDGF-BB treatment is available from a previous study [47] and is shown in
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Figure S1. This data obtained with the EdU assay allowed observation of the short term effect (24 h post
stimulation) of both molecules on tenocyte proliferation. Under serum+ conditions, AA concentrations
(1–50 µg/mL) led to a dose-dependent increase in tenocyte proliferation (% of EdU-positive cells).
However, only 50 µg/mL AA led to a significantly higher cell proliferation when compared to no
supplementation or 1 µg/mL AA (Figure 1A). Under serum-free conditions, the tenocyte proliferation
was not affected by any AA concentration, with very low proliferation rates of approximately 10%
(Figure 1B). On the other hand, there was a significant, dose-dependent increase in cell proliferation with
10–50 ng/mL PDGF-BB concentrations under serum-free conditions (Figure S1B), while no significant
differences were observed under serum+ conditions for any PDGF-BB concentration (Figure S1A).
Figure 1. Effect of AA on tenocyte proliferation. Representative CLSM images from the EdU
proliferation assay and EdU-positive cells [%] for each AA concentration (µg/mL) tested in (A) serum+
conditions and (B) serum-free conditions. The effect of different PDGF-BB concentrations on tenocyte
proliferation assessed by the EdU assay is presented in Figure S1. The total EdU-positive cells [%]
was calculated as EdU positive cells (pink) in relation to the total cell number (DAPI stained, blue).
Scale bars: 100 µm. (Data is shown as mean ± standard deviation, ** p < 0.01, *** p < 0.001 obtained by
one-way ANOVA).
2.2. Tenocyte Morphology and ki-67 Expression Changes under Different Conditions over Time
Phalloidin staining for cell morphology visualization through actin cytoskeleton staining, together
with ki-67 staining as a proliferation marker, was performed for tenocytes grown in medium
supplemented with AA (10 µg/mL), PDGF-BB (25 ng/mL) or both molecules (10 µg/mL AA + 25 ng/mL
PDGF-BB), for 7 days (day 1, 3 and 7) (Figure 2). In Figure 2, changes in cell morphology over time
in serum+ conditions can be observed. While on day 1 the cell culture for all the conditions was a
mixture of spread out cells and more elongated ones, the cell morphology changed in the supplemented
cultures to a more longish, spindle-shaped type on day 3, which was even more pronounced on day 7.
Compared with the control (no supplementation) and PDGF-BB treated cell cultures, the addition of
AA revealed a higher cell confluence over time, with extremely thin and long cells on day 7. Similarly,
based on cell density, the same effect was observed for the culture with AA + PDGF-BB treatment. In
contrast, cells in the control condition on day 7 had changed to a longish morphology when compared
to earlier time points, but still were not as elongated and dense as in the presence of AA or PDGF-BB
(qualitative inspection).
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Figure 2. Effect of AA and PDGF-BB on tenocyte proliferation and morphology in cell culture.
Representative CLSM images of tenocytes cultured in serum+ medium for a period of 7 days and
supplemented with either AA (10 µg/mL), PDGF-BB (25 ng/mL), combination of AA (10 µg/mL) +
PDGF-BB (25 ng/mL), or untreated (control). Cells were stained with phalloidin (green) for visualizing
the cytoskeleton, ki-67 (red) as a proliferation marker, and DAPI (blue). Scale bars: 100 µm.
From the representative images in Figure 2, it can be observed that AA, PDGF-BB, and combined
supplementation led to an increasing number of ki-67 positive cells over time, with the highest cell
proliferation on day 3, when compared to the control condition.
2.3. AA and PDGF-BB Supplementation Differently Affected Expression of Tendon Specific Markers and
ECM Proteins
To determine what effect AA and PDGF-BB supplementation might have on gene expression in
tenocytes, the transcription of different tendon-specific markers, ECM proteins, and genes involved in
ECM turnover was analyzed.
During tendon repair, there is usually a 6-week cellular phase after an initial inflammatory phase.
In the cellular phase, where tenoblasts invade the wound site, among other cells, upregulation of
tenomodulin is highly important because tenomodulin regulates tenocyte proliferation and the growth
of collagen fibers [48–50]. In addition, the transiently expressed tenascin-C plays a pivotal role in
this phase, as it modulates proliferation, fiber alignment, and orientation [51]. Although Mohawk is
particularly involved in the tenogenic differentiation of stem cells [52] by preventing osteogenic and
chondrogenic differentiation [53], it also supports tendon repair by improved collagen deposition [54].
As for the remodeling of the matrix and the wound repair, after the initial fibronectin deposited acts
as a template, collagen III and later on collagen I are deposited by the tendon cells. Proteins, such as
biglycan and decorin, play an important role as they bind water and are therefore add to the elasticity
of the tendon matrix [55]. For remodeling, matrix metalloproteases (MMPs) as well as their inhibitors
(TIMPs) are of high importance [56] and are therefore included in the following gene expression
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analysis. The expression of the genes of interest was analyzed at three different time points, i.e., day
3, 7 and 14, and the relative expression was normalized to the control (non-supplemented serum+
medium) (Figure 3).
Figure 3. Gene expression of tenocytes supplemented with AA or PDGF-BB over 14 days in 2D
cell culture. (A) Box-plots of time-dependent (day 3, 7 and 14) relative gene expression in tenocytes
supplemented with AA (50 µg/mL), normalized to non-stimulated tenocytes and (B) box-plots of
time-dependent (day 3, 7 and 14) relative gene expression in tenocytes supplemented with PDGF-BB
(25 ng/mL), normalized to non-stimulated tenocytes. In the experiments with AA, tenocytes isolated
from three different rabbits were used (biological replicates n = 3), while for PDGF-BB experiments,
cells from four different rabbits were used (biological replicates n = 4). Technical replicates in cell
culture were performed in triplicate and in PCR experiments in duplicate. Significant differences were
based on unpaired t-tests for each time point (whiskers on the box-plots represent standard deviation,
* p < 0.05, ** p < 0.01, *** p < 0.001).
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Upon AA treatment, a trend of increase in the expression of collagen I (col1A1 and col1A2),
Mohawk and alpha-SMA over time can be observed (Figure 3A, first and second panel), but with
big variation among results gained from tenocytes of different rabbits. Fibronectin was significantly
downregulated in the first week of AA treatment, while on day 14 there was an increase in its expression,
but with large variation among animals. Both aggrecan and biglycan were downregulated in the first
week, but only biglycan downregulation was significant also on day 14. Tenascin-C and tenomodulin
expression were significantly downregulated, while decorin was significantly upregulated. Collagen III
expression (col3A1) showed a slight decrease over time but without significant changes, similar to ki67
expression. MMP-2 expression was upregulated significantly on day 7 and 14, which was accompanied
by a very similar and significant increase in TIMP-2 gene expression on day 3 and 14. While TIMP-1
expression was not affected by AA supplementation, MMP-9 expression was significantly increased on
day 7, followed by a decrease in expression on day 14.
On the other hand, PDGF-BB supplementation did not lead to significant changes in the collagen
I (col1A1 and col1A2) expression over time (Figure 3B, first panel). Although there was a significant
downregulation in col1A2 on day 3 followed by a trend of upregulation on day 7 and 14, there was
no significant change in col1A1 for all time points considered here. Collagen III was significantly
downregulated on day 7, but without significant change on day 14. In contrast, fibronectin was
significantly upregulated over time, starting on day 3 and was even more pronounced on day 14
(two-fold increase). Aggrecan was initially upregulated (day 3), without significant changes at later
time points, while biglycan expression showed a significant increase on day 14. As for decorin, another
typical tendon marker besides biglycan, there was a small but significant downregulation on day 7,
without significant changes at later time points.
The proliferation marker ki67 was significantly upregulated on day 3, suggesting increased
proliferation at this time point. However, expression decreased over time with significant
downregulation on day 14 (Figure 3B, second panel). The most substantial effect of PDGF-BB
supplementation on the tendon-specific markers (tenomodulin, Mohawk, and tenascin-C) was observed
on the Mohawk gene expression, where significant downregulation was already observed on day 7,
and the trend continued on day 14. Expressions of tenomodulin and tenascin-C were not significantly
affected by PDGF-BB supplementation. MMP-9 expression varied a lot throughout all time points, but
it showed a slight upregulation trend, while MMP-2 expression showed a significant downregulation
on days 7 and 14. A downregulation trend was also observed for TIMP1 and TIMP2 with significant
changes at later time points, i.e., days 7 and 14.
2.4. AA Supplementation Increased ECM Deposition by Tenocytes
Figure 4 shows the effect of AA and PDGF-BB on the ECM synthesis in tenocyte cell culture,
i.e., collagen I and fibronectin deposition by tenocytes over time (day 3, 7 and 14). As a comparison,
TGF-β1 was also used as a treatment because it is known to stimulate ECM synthesis [57,58]. All the
conditions were compared to tenocytes grown only in serum+ culture medium (control), and tenocytes
isolated from three different rabbits were assessed (Figure 4, Figures S2 and S3). Since the medium in
all conditions was supplemented with 30 µg/mL fibronectin isolated from human plasma [59]; thus,
the staining of fibronectin detects both newly synthesized fibronectin by the rabbit tenocytes, as well as
the assembled fibronectin supplemented in the medium. In all tenocyte cultures, the fibronectin matrix
is denser in the PDGF-BB, TGF-β1, or AA conditions when compared to the control, and the density of
the fibronectin matrix increases over time, from day 3 to 14. Moreover, in the TGF-β1 condition, on
average, the cell number is lower than in the PDGF-BB or AA condition (due to the proliferative effect of
both molecules). However, the fibronectin matrix is as dense as in the other two conditions, suggesting
that TGF-β1 supplementation leads to an increase in fibronectin deposition by tenocytes. Quantitative
analysis of the fibronectin signal normalized to the total cell number in each condition (Figure S4)
indeed showed an increase in fibronectin deposition upon TGF-β1 stimulation when compared to the
other conditions, especially after 14 days in culture. These results were observed for tenocytes isolated
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from all three animals. The increase in fibronectin deposition was also confirmed for the AA treatment.
On the other hand, normalization of the fibronectin signal to the total cell number revealed that while
a denser matrix was present in the PDGF-BB condition, the fibronectin deposited per cell did not differ
a lot from the control condition and it varied between the different tenocyte isolations (Figure S4).
Figure 4. Extracellular matrix deposition by tenocytes stimulated with PDGF-BB, AA or TGF-β1.
Representative CLSM images of collagen I or fibronectin staining (green) and cell nuclei DAPI staining
(blue) of rabbit tenocytes cultured in vitro in 2D, treated with PDGF-BB (50 ng/mL), TGF-β1 (10 ng/mL),
AA (50 µg/mL) or untreated (control) on day 3, 7 and 14. For additional data of the same experiment
performed with tenocytes isolated from two other animals and for quantification of the fibronectin
deposition under the different treatments, we refer to the figures in the supporting information. Scale
bars: 100 µm.
Upon PDGF-BB supplementation, an increase in cell number (DAPI staining) was observed when
compared to the control condition, but no collagen I synthesis was detected in any of the samples at
all time points, for any of the cell cultures from all animals. TGF-β1 treatment led to an increase in
collagen I on day 7 and day 14, but only for tenocytes isolated from two animals (Figure 4 and Figure
S2). As early as day 3, no visible collagen I deposition was present in any of the samples with TGF-β1
treatment. On the other hand, AA addition led to significant collagen I deposition already on day 3. In
the presence of AA, tenocytes from all animal donors deposited collagen on day 3, 7 and 14, and over
time the collagen I matrix is becoming denser as observed in Figure 4, Figures S2 and S3.
In addition to assessing AA and PDGF-BB supplementation in a cell medium and 2D environment,
it was also investigated what the effect would be of these molecules when they are incorporated and
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released over time from electrospun scaffolds, in a 3D environment. Biocompatible scaffolds can play a
role as a key delivery platform for cell therapy in various tissue engineering approaches, and bioactive
scaffolds would also be beneficial for this purpose. A convenient and easy method for production
of bioactive scaffolds is emulsion electrospinning, which allows a sustained release profile of the
incorporated molecule over time [28]. Previous research has shown that both AA and PDGF-BB can be
successfully incorporated into electrospun scaffolds and released in a sustained manner over a period
of 30 days [47].
Primarily, cell culture over time and ECM production onto the scaffolds were examined by SEM,
as well as collagen I and fibronectin staining (Figure 5). Representative SEM images in Figure 5A show
a significant increase in ECM production on the scaffolds releasing AA, which is already visible on day
3. Continuous coverage of the scaffold surface by cells and deposited ECM is visible on day 14, which
is not the case in the control group (pure scaffolds) or on scaffolds with incorporated PDGF-BB. The
staining of collagen I and fibronectin confirms these results (Figure 5B). While no collagen I deposition is
observed for tenocytes seeded onto pure scaffolds and scaffolds with PDGF-BB, a significant deposition
is visible when cells were cultured on the bioactive scaffolds containing AA. Collagen I deposition
stimulated by the released AA over time from the scaffolds is visible already on day 3. These results
suggest that AA is released over time from the bioactive electrospun scaffolds and that it retains its
bioactivity by stimulating cell proliferation and ECM deposition.
Figure 5. Tenocytes cultured on pure and bioactive scaffolds over a period of 14 days. (A) SEM images
of tenocytes, seeded on bioactive electrospun DP scaffolds, containing either AA, PDGF-BB (bioactive
scaffolds) or none of them (pure scaffold). The cell morphology and ECM deposition overtime is
observed on the SEM images. (B) Representative CLSM images of collagen I (green), fibronectin
staining (red) and cell nuclei DAPI staining (blue) of rabbit tenocytes cultured onto the electrospun
scaffolds. Scale bars: (A) 20 µm and (B) 50 µm.
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3. Discussion
In order to treat tendon diseases and support tendon regeneration, cell-based therapy, as well
as other tissue engineering approaches, are viable options. Although it is self-evident that tenocytes
might be a valuable cell source for tissue engineering approaches to treat tendon injuries and diseases,
a pre-treatment step in culture could enhance their regenerative potential. Particular attention during
the selection of pre-treatment options is paid to accelerate cell expansion by increasing cell proliferation.
Therefore, the main aim of this study was to assess the effects of PDGF-BB and AA in vitro on
rabbit Achilles tenocyte culture, as they have been proposed as biomolecules of interest for tendon
healing, as well as biochemical supplementation, which affects cell proliferation and ECM synthesis of
tenocyte culture.
PDGF-BB has been studied as a growth factor of interest to be delivered to support tendon
healing upon injury/rupture due to its mitogenic, chemotactic and angiogenic properties [28]. There
are studies on tenocyte proliferation, dealing with the effects of PDGF-BB, but also of other growth
factors [60], with a particular emphasis on using tenocytes for the population of scaffold materials
or for re-populating previously decellularized matrices [61]. On the other hand, the efficacy of AA
supplementation after musculoskeletal injuries with respect to collagen synthesis has been investigated
widely [62]. As a cofactor for prolyl hydroxylase and lysyl hydroxylase, AA plays a pivotal role in
the synthesis of collagen [63,64] and, as such, can play an important role in the healing of connective
tissue. Recently, a proof of concept study showed that AA led to better healing in a rat Achilles tendon
injury model, particularly in combination with thyroid hormone T3 [65]; with a significant increase in
cell proliferation, more regular fiber structure and higher collagen I to collagen III ratio, indicating
an accelerated healing process [21]. Moreover, AA supplementation also stimulated Achilles tendon
healing in rats after complete rupture [46]. Thus, in this study, the impact of both biomolecules on
tenocyte proliferation, morphology, gene expression, and ECM deposition of rabbit Achilles tenocytes
was assessed.
One of the findings in our study was a dose-dependent increase of tenocyte proliferation upon
stimulation with both biomolecules, but under different medium conditions. When short term (24 h
post supplementation) tenocyte proliferation was assessed, for PDGF-BB supplementation the effect
was stronger under serum-free conditions, while for AA supplementation under serum+ conditions
(Figure 1 and Figure S1). This could be due to the fact that the effect of PDGF-BB is masked by
the presence of serum in the medium, which contains other growth factors and molecules that
support cell growth, so its effect on tenocyte proliferation and DNA synthesis is clearly isolated under
serum-free conditions. On the contrary, AA stimulation led to a visible, dose-dependent increase in
cell proliferation only in serum+ medium. It has been shown in adipose-derived stem cells [66] or
hepatocytes [67] that AA inserts its effect on proliferation by activating MAPK signaling, and it could
be that in the short term (24 h) assessment of tenocyte proliferation, the effect is not strong enough.
Complimentary to the short term cell proliferation, tenocyte proliferation over time in serum+
medium was also assessed by looking at ki-67 expression as a proliferation marker. Cell proliferation in
both treatments peaked on day 3 of incubation (Figure 2), and qualitatively PDGF-BB supplementation
showed an increase in cell proliferation in serum+ condition as well.
These findings on the dose-dependent effect of both molecules on cell proliferation are in
agreement with previous studies that have reported similar results. Similar concentrations of PDGF-BB
(10–50 ng/mL) have been shown to promote tenocyte proliferation in vitro best [28,39,68,69] and also
in combination with other growth factors, like basic fibroblast growth factor (bFGF) and insulin-like
growth factor (IGF-1) [39,61]. In addition, other growth factors, such as VEGF, have also been tested.
For that purpose, human tenocytes were cultivated in the presence of 5, 10 and 20 ng/mL VEGF,
respectively [37]. Not only was proliferation significantly increased at 20 ng/ mL VEGF compared
with the control, but also gene expression was significantly affected. A similar concentration of AA
(10–50 µg/mL) led to an increase in tenocyte proliferation in previous studies as well [38]. Both
molecules and a combination of them led to higher cell density over time (within a period of 7 days)
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and cell morphology change from more spread out to spindle-shaped cells (Figure 2), typical for
tenocyte morphology, similar as reported in other studies as well [31].
An important finding in this study was the fact that both molecules affected the gene expression
of several ECM proteins and tendon markers, but with different trends. AA led to an increasing
trend in collagen I (col1A1 and cola1A2), Mohawk and α-SMA gene expression, and a significant
increase in decorin, MMP-2, and TIMP2 expression (Figure 3A). Additionally, it led to a significant
downregulation of fibronectin, aggrecan, biglycan, tenascin-C, and tenomodulin, the latter being two
important tenocyte markers besides scleraxis [70] for which unfortunately a primer set for the rabbit
species was unavailable. In contrast, tenocytes cultivated in the presence of PDGF-BB exhibited a
prominent upregulation of fibronectin and biglycan after 2 weeks, while a significant downregulation
of Mohawk, MMP-2, TIMP-2, and TIMP-2 was determined (Figure 3). As for the proliferation marker
ki67, an upregulation was found on day 3, which was downregulated later on day 14, but this peak
was timely coherent with the immunostaining performed for ki-67 in tenocyte culture (Figure 2). In
terms of ECM deposition, as assessed by collagen I and fibronectin immunostaining in tenocyte culture
over time, it was determined that AA strongly supported collagen I synthesis and also led to increasing
fibronectin deposition, while PDGF-BB only led to a denser fibronectin matrix when compared to the
control condition, but not to a visible collagen I deposition (Figure 4).
A similar trend was observed when tenocytes were seeded onto bioactive scaffolds that released
in a sustained manner the biomolecules, where more prominent matrix formation and an increase
in cell density were visible on scaffolds with AA when compared to ones with PDGF-BB or pure
scaffolds (control) (Figure 5). Such results stand in agreement with the findings from Piran et al., where
PDGF-BB released from chitosan nanoparticles showed a significant increase in the proliferation of
fibroblasts [71].
The increase of collagen I synthesis by AA supplementation observed at the protein level, was
supported by the gene expression data as well, showing an upregulation of collagen I, standing in
agreement with previous studies [31,62]. A similar upregulation trend was observed for Mohawk,
which was suggested to play an important role in collagen I production in tenocytes [52,53,72].
Fibronectin gene expression was downregulated by AA supplementation, while qualitatively a slight
increase was visible in fibronectin deposition in culture. In contrast, stimulation by PDGF-BB led to
significant upregulation of fibronectin accompanied by a small increase in collagen I on day 14 and a
significant downregulation of Mohawk expression, in agreement with a slight increase in fibronectin
deposition in culture and no visible deposition of collagen I. These results suggest that PDGF-BB
supplementation led to expression and deposition of fibronectin as a first matrix scaffolding component
for further ECM components, and while this process was ongoing, no upregulation or increase in
collagen I expression took place at subsequent time points. On the other hand, when collagen I
synthesis was stimulated by AA, fibronectin expression was decreased. Since it is known that these
two ECM components are in close interplay, these observations are in alignment with previous research
on the dynamics of fibronectin and collagen I [73–75].
Another component that has interactions with fibronectin is the glycoprotein tenascin-C, which
is transiently elevated during injury and regulated by mechanical stress [51,76]. Tenascin-C gene
expression was downregulated by AA, while being upregulated by PDGF-BB supplementation
(Figure 3). Since tenascin-C and fibronectin assembly are interdependent [77], simultaneous
upregulation or downregulation of tenascin-C and fibronectin, as observed in each supplementation,
was expected and confirmed. Another explanation for the opposite impact on the expression of this
gene might be related to the activation of different signaling pathways. While PDGF-BB regulates
tenascin-C expression via the PI3K-Akt signaling pathway [76], a major player for tenascin-C regulation
is the homeobox protein family [78], and AA is known to interact with Nanog [79,80], a homeobox
protein, via the JAK/STAT signaling pathway [79]. Hence, although not elucidated in detail up to date,
AA may influence tenascin-C gene expression by other regulatory pathways than PDGF-BB does; and
JAK/STAT pathway may play a role. In addition, AA has been reported to act via Wnt signaling [81,82],
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but the regulation of tenascin-C expression by the Wnt/β-catenin signaling pathway has not been
reported for tenocytes yet, but only for macrophages [83] or smooth muscle cells [84].
A study by Orfei et al. on the in vitro induction of tendon-specific markers revealed induction of
decorin protein expression by AA [30], which was observed in this study as well; AA stimulation led
to a significant increase of decorin gene expression on day 7 and 14. However, PDGF-BB stimulation
led to the opposite, at least on day 7, when a downregulation in decorin gene expression was
observed. An opposite effect was observed for the gene expression of biglycan: downregulated by
AA, but upregulated in the presence of PDGF-BB. Hence, biglycan and decorin experienced opposite
changes in gene expression by the two biomolecules, and their changes may be dependent on the
upregulation/downregulation and the dynamic interplay with the other matrix components.
Additionally, AA stimulation led to a significant increase in MMP-2 and TIMP-2 gene expression.
Increases in MMPs are particularly associated with mechanical loading. For example, a repetitive
stretching of human tenocytes for 5 days evoked a significant increase of MMP-2 on gene and protein
expression levels [85,86]. Here, an increase under static cultivation conditions in vitro was found.
MMP-2, the most abundant MMP [87], is known to degrade collagen fibers and its overexpression in
aggressive tumors has been well described [88,89]. Its activation and activity are critically influenced
by the tissue inhibitor of matrix metalloprotease, TIMP-2 [90]. As we found both genes significantly
upregulated in the presence of AA, it can be concluded that matrix turnover and remodeling are
enhanced in tenocyte culture supplemented with AA, which is of great importance during wound
healing. These results also align with the observations in increased ECM synthesis, i.e., collagen I in
the presence of AA.
Although several effects of PDGF-BB and AA on tenocyte culture in vitro could be shown in this
study, there are some limitations. As mentioned above, scleraxis as a typical tenocyte marker gene
could not be assessed because the gene for the rabbit species is not available. In addition, it would
have been interesting to assess quantitatively the cell proliferation over a longer period, where we have
assessed it only for 24 h with the EdU assay. It was only qualitatively assessed with ki-67 as a marker
for proliferation over 7 days. Finally, different concentrations used in different experiments, such as for
the extracellular matrix formation and gene expression, may hamper a direct comparison of the results.
In conclusion, this in vitro study shows that both biomolecules tested on rabbit Achilles tenocyte
culture may act beneficially during tenocyte expansion prior to utilization for different tissue engineering
approaches or application in vivo. AA and PDGF-BB enhanced tenocyte proliferation and accelerated
the deposition of ECM components, such as collagen I and fibronectin, but with different dynamics in
the ECM synthesis. AA led to a particularly strong increase in collagen I deposition. Interestingly, on the
gene expression level, the two biomolecules led to different changes in some of the investigated markers
and most notably affect collagen and fibronectin expression in opposite ways. While AA upregulated
collagen I, Mohawk, decorin, MMP-2, and TIMP-2 expression, these markers were downregulated by
PDGF-BB. On the other hand, PDGF-BB led to an upregulation of fibronectin, biglycan and tenascin-C,
whereas AA showed downregulation of these markers. The interplay between the different ECM
components and different signaling pathways involved may explain such outcomes. In order to
conclusively determine the mechanisms standing behind these different findings, further studies will be
needed. However, this knowledge can be used for improved tenocyte culture expansion and maybe a
combination or subsequent supplementation of both biomolecules may lead to optimal tenocyte culture
conditions. Like this, these findings may pave the way for improved cell-based tendon therapies.
4. Materials and Methods
4.1. Isolation of Rabbit Achilles Tenocytes
Rabbit tenocytes were isolated from Achilles tendons of New Zealand White rabbits using the
cell migration method. Briefly, tendons were extracted from the animals and washed with Hank’s
Balanced Salt Solution (1x HBSS with Ca2+ and Mg2+, Thermo Fisher Scientific, Rockford, IL, USA)
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with 200 µg/mL gentamicin (Biowest, Nuaillé, France) and 2.5 µg/mL amphotericin B (Biowest, Nuaillé,
France). The tendons were cleaned from the surrounding tissue and the central part of the tendons was
cut into very small pieces (< 2 mm) and washed three times in 1x HBSS buffer. Afterwards, multiple
tissue pieces were placed into each tissue culture plate (PrimariaTM, Corning, New York, NY, USA)
and a drop of cell culture medium (Ham’s F12 (Biowest, Nuaillé, France), 10% FBS (Biowest, Nuaillé,
France), 200 µg/mL gentamicin, and 2.5 µg/mL amphotericin B) was added onto each tissue piece.
Tissues were allowed to attach onto the cell culture plates for 2 h at 37 ◦C and 5% CO2 before adding
10 mL of cell culture media in each plate. The plates with the tissues were not moved for the first 5 days,
to decrease tissue detachment upon plate movement and to allow cells to start migrating out from the
tissues. The first medium change was done after 5 days, and subsequently, the culture medium was
changed every third day. After approximately 2 weeks, tissue pieces were removed from the plates,
and cells were allowed to proliferate for 1 week more before cryopreservation. Cryopreserved rabbit
tenocytes were thawed, resuspended in culture medium (Ham’s F12 with 10% FBS and 50 µg/mL
gentamicin) and cultured at 37 ◦C and 5% CO2 with media being changed every second day. Tenocytes
between passages 2 and 4 (P2–4) were used for all experiments (Approval by the veterinary office of
Canton Zurich, ZH255/15, 21st April 2016.
4.2. EdU Proliferation Assay
The effect of AA (L-Ascorbic acid 2-phosphate sesquimagnesium salt hydrate, Sigma-Aldrich,
Buchs, Switzerland) and recombinant human PDGF-BB (Peprotech, London, UK) on rabbit tenocytes
were tested by an increase in cell proliferation assessed by the Click-iT EdU proliferation kit (Invitrogen,
Carlsbad, CA, USA). The proliferative effect was studied in serum+ (Ham’s F12 with 10% FBS and
1% P/S) and serum-free (Ham’s F12, 1x RPMI vitamins solution (Sigma-Aldrich, Buchs, Switzerland),
1x non-essential amino acids solution (Invitrogen, Carlsbad, CA, USA) and 1% P/S) culture medium.
AA concentrations of 1, 10 and 50 µg/mL and PDGF-BB (Peprotech, London, UK) concentrations
of 10, 25 and 50 ng/mL were tested. Cells were seeded in 8-well µ slides, ibiTreat (Ibidi, Munich,
Germany, growth area per well: 1.0 cm2) at 4 × 104 cells mL-1 (300 µL per well). In the case of tenocytes
supplemented with PDGF-BB, cells were first serum-starved for synchronization with a daily change
of serum-free medium over 3 days. After 3 days, different PDGF–BB concentrations in serum-free
or serum+ medium, respectively, together with 10 µM 5-ethynyl-2′-deoxyuridine (EdU) were added
and incubated for 24 h at 37 ◦C and 5% CO2. In the case of tenocytes supplemented with AA under
serum+ conditions, there was no cell synchronization performed with cell starvation, but rather
cells were directly seeded in serum+ medium and after 24 h, different AA concentrations in serum+
medium together with 10 µM 5-ethynyl-2′-deoxyuridine (EdU) were added and incubated for 24 h at
37 ◦C and 5% CO2. Tenocytes supplemented with AA under serum-free conditions underwent cell
synchronization with serum-starvation as the cells treated with PDGF-BB under serum-free conditions.
After 3 days, different PDGF–BB concentrations in serum-free or serum+ medium, respectively, together
with 10 µM 5-ethynyl-2′-deoxyuridine (EdU) were added and incubated for 24 h at 37 ◦C and 5% CO2.
Cells were then fixed in 4% PFA, permeabilized with 0.1% TritonX-100 in 1x PBS and EdU stained
according to the kit’s protocol. Cell nuclei were stained with 5 µg/mL-1 4′6-diamidino-2-phenylindole
dilactate (DAPI) for 10 min. Samples were imaged with a confocal microscope (SP5, Leica Microsystems,
Wetzlar, Germany) with 20x/0.7 N.A. objective and 30 random images were taken per sample (n = 6).
The total EdU-positive cells [%] was calculated as EdU positive cells in relation to the total cell number
in each image. Results are expressed as EdU-positive cells [%] ± standard deviations.
4.3. Tenocyte Morphology under Different Conditions
To assess the effect of AA and PDGF-BB on the morphology of tenocytes over time, as well as
to additionally assess the cell proliferation at each time point, cells were cultured and stained with
Phalloidin and ki-67. Cells were seeded in 8-well µ slides, ibiTreat (growth area per well: 1.0 cm2), in
serum+ medium (1.4 × 104 cells/mL (300 µL per well)). Cells in serum+ medium were cultured in the
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respective conditions (10 µg/mL AA, 25 ng/mL PDGF-BB, 10 µg/mL AA + 25 ng/mL PDGF-BB or just
serum+ medium) over a period of 7 days and the medium was changed every 2 days. Desired PDGF-BB
and AA concentrations were added freshly to the medium every time during medium exchange, for the
whole duration of the experiment. Samples were fixed on day 1, 3 and 7 with 4% paraformaldehyde
(PFA). Cells in serum-free medium were starved and then stimulated with the respective supplemented
serum-free media, and fixed on day 1 with 4% PFA. Samples were permeabilized (0.1% Triton X-100
(Sigma-Aldrich, Buchs, Switzerland) in 1x PBS) and blocked with 3% bovine serum albumin (BSA)
(Sigma-Aldrich, Buchs, Switzerland) for 1 h at room temperature. Afterward, rabbit anti ki-67 antibody
(ab15580, Abcam, Cambridge, MA, 1:500 dilution) in 3% BSA was incubated with the samples at 4 ◦C,
overnight. The next day, samples were washed three times with 1x PBS and incubated with secondary
goat anti-rabbit Alexa555 antibody (A21249, Invitrogen, Carlsbad, CA, USA, 1:500 dilution) in 3% BSA
in 1x PBS for 1 h at room temperature. Samples were washed and then incubated with Phalloidin
(A12379, Invitrogen, Carlsbad, CA, USA, 1:500 dilution) for 1 h at room temperature, followed by a
sample wash. In the end, samples were incubated with DAPI (5 µg/mL) for 10 min at room temperature,
washed and imaged with confocal microscopy (SP5, Leica Microsystems, Wetzlar, Germany) using
20x/0.7 N.A. objective. Ten images from each sample (n = 3) were acquired.
4.4. RNA Isolation and Quantitative Real-Time PCR Analysis
In order to determine the effect of AA and PDGF-BB supplementation on the gene expression of
tenocytes in vitro over time, rabbit tenocytes were isolated and cultured as described in the sub-section
Isolation of rabbit Achilles tenocytes and seeded into 12-well plates (TPP, Trasadingen, Switzerland,
growth area per well: 3.60 cm2) with a density of 4 × 104 cells/ well. Cells were allowed to attach
overnight before the medium was exchanged to medium with PDGF-BB (25 ng/mL) or AA (50 µg/mL)
or without any supplementation (Ham’s F12, 10% FBS, 50 µg/mL gentamicin). Desired PDGF-BB
and AA concentrations were added freshly to the medium every time during medium exchange, for
the whole duration of the experiment. The medium was changed every second day, and cells were
stimulated with PDGF-BB or AA for a total of 14 days. Samples were collected on day 3, 7 and 14.
Rabbit tenocytes from four different animals were used (n = 4) for the experiments with PDGF-BB
supplementation from three different animals (n = 3) for the experiments with AA supplementation.
In all the experiments, triplicates of cell culture samples for each animal were run. At the respective
time point, total RNA was isolated using the RNeasy Plus Mini Kit (Qiagen, Hilden, Germany) with
RNase-free DNase treatment (Qiagen, Hilden, Germany), following the manufacturer’s protocol. For
reverse transcription (RT), 500 ng of total RNA was reverse transcribed into cDNA in a reaction volume
of 20 µL using the iScript™ Advanced cDNA Synthesis Kit (Bio-Rad, Cressier, Switzerland). Real-Time
PCR reactions were performed on the resulting cDNA samples (5 ng cDNA per reaction), using the
CFX Connect™ Real-Time PCR Detection System (Bio-Rad, Cressier, Switzerland) and SsoAdvanced™
SYBR® Green Supermix (Bio-Rad, Cressier, Switzerland). The PCR reactions were incubated at 95 ◦C
for 3 min, followed by 39 cycles of 95 ◦C for 10 s and 62 ◦C for 30 s. All samples were run in technical
duplicates. The primer sequences used are outlined in Table S1. All primers were synthesized by
Microsynth, Balgach, Switzerland. Relative expression analysis was performed using the comparative
2−∆CT method with 18S rRNA as a reference gene, which was stable over the two conditions analyzed.
Results are presented as fold change normalized to control, i.e., compared to samples cultivated without
PDGF-BB or AA. Data is shown in box-plots, where the whiskers represent the standard deviation of
the data.
4.5. Extracellular Matrix Production under Different Conditions
In order to test the effect of AA, PDGF-BB, or TGF-β1 supplementation on collagen I and fibronectin
production in vitro, tenocytes were seeded into 8-well µ slides, ibiTreat (growth area per well: 1.0 cm2)
at 7 × 104 cells/mL (300 µL per well) in a cell culture medium. Cells were allowed to attach overnight,
and the following day the cell culture medium was exchanged with cell culture medium supplemented
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with 50 ng/mL PDGF-BB or 10 ng/mL TGF-β (PeproTech, London, UK) or 50 µg/mL AA. Additionally,
the cell culture medium in all conditions was supplemented with 30 µg/mL fibronectin (unlabeled)
isolated from human plasma [59]. A culture medium supplemented only with fibronectin was used as
a control condition. The culture medium was exchanged every 2 days. Desired PDGF-BB and AA
concentrations were added freshly to the medium every time during medium exchange, for the whole
duration of the experiment.
For immunofluorescence staining, separate samples were prepared and stained for collagen I and
fibronectin deposition assessment. For collagen I staining, at the respective time points (day 3, 7 and
14), samples were washed with 1x PBS, and then culture medium with mouse anti-collagen I antibody
(ab90395, Abcam, Cambridge, MA, USA, 1:200 dilution) was added to unfixed samples and incubated
for 1 h at 37 ◦C. Afterward, samples were washed three times with 1x PBS (pH 7.4) and fixed for 10 min
with 4% PFA and washed again. Samples were blocked with 3% BSA in 1x PBS for 1 h. Secondary
donkey anti-mouse Alexa-488 antibody (A-21202, Invitrogen, Carlsbad, CA, USA, 1:500 dilution) in 3%
BSA in 1x PBS was added afterward and incubated for 1 h at room temperature. Nuclei were stained
with 5 µg/mL DAPI for 10 min and washed afterward. For fibronectin staining, the samples were
washed with 1x PBS, fixed for 10 min with 4% PFA, and washed again. Afterward, they were blocked
with 3% BSA in 1x PBS for 1 h and subsequently incubated with mouse anti-fibronectin antibody (F0791,
Sigma-Aldrich, Buchs, Switzerland, 1:200 dilution) overnight at 4 ◦C. The next day, samples were
washed and incubated with secondary donkey anti-mouse Alexa-488 (A-21202, Invitrogen, Carlsbad,
CA, USA 1:500 dilution) antibody for 1 h at room temperature. Nuclei were stained with 5 µg/mL
DAPI for 10 min and washed afterwards. Samples were imaged with confocal microscopy (SP5, Leica
Microsystems, Wetzlar, Germany) with 20x/ 0.7 N.A. objective, and z-stacks were acquired. Four images
per sample (n = 3) for each condition were acquired. Confocal images are presented as maximum
projections of the z-stacks.
4.6. Tenocyte Culture on Electrospun Scaffolds with Incorporated AA or PDGF-BB
Emulsion electrospun scaffolds made from DegraPol® (DP) (Ab medica, Milan, Italy) with
incorporated PDGF-BB (diluted in 0.1% BSA in distilled water at a concentration of 40 µg/mL) were
produced as reported previously [47]. For the production of emulsion electrospun scaffolds with
incorporated AA, AA was dissolved in water at a concentration of 50 mg/mL and 200 µL of this
stock solution were added drop wise to 5 g of 12 wt% DP polymer solution (dissolved in mixture
of chloroform/HFP (80:20) (Sigma-Aldrich, Buchs, Switzerland), under stirring for 2 min at 500 rpm.
Afterwards the mixture was sonicated with a probe ultrasonicator for 2 min at 50% amplitude.
Immediately afterward, the emulsion was used for electrospinning as reported previously [47].
After electrospinning, the scaffolds were dried in vacuum overnight. Before cell seeding, scaffolds
were UV sterilized for 30 min. Afterward, scaffolds were shortly wetted in 50% ethanol, cut in small
squares that could fit in one well of 8-well µ slides, ibiTreat (growth area per well: 1.0 cm2), rinsed
three times in water, put into the 8-well µ slides, and washed one time with culture medium. Culture
medium was removed from each well, and tenocytes with a density of 4 × 104 per well were seeded on
top of the scaffolds containing AA, PDGF-BB, or no biomolecule (pure scaffolds) (n = 3). The culture
medium, containing 30 µg/mL fibronectin, was changed every 2 days. At each respective time point
(day 3, 7 or 14), the culture medium was aspirated, samples were washed one time with 0.1 M PIPES
(pH 7.4) buffer and samples were fixed in 4% glutaraldehyde (Sigma-Aldrich, Buchs, Switzerland) at
4 ◦C, overnight. The next day, samples were washed in 0.1 M PIPES buffer and dehydrated by placing
them in a series of ascending concentration of ethanol (30%, 50%, 70%, 80%, 95% (5 min each step), and
100% (10 min, twice)). Afterwards, the samples were chemically dried in HMDS/ethanol mix (3:1, 1:1,
1:3 and pure HMDS, each for 15 min). After allowing the HMDS to evaporate completely overnight,
the samples were mounted on SEM stubs, sputter coated (SCD500, Bal-tec, Balzers, Lichtenstein) with
platinum in order to obtain 10 nm coating and then examined by scanning electron microscope (Zeiss
SUPRA 50 VP, Zeiss, Cambridge, UK) at an accelerating voltage of 5 kV.
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For assessing collagen I and fibronectin deposition onto the electrospun scaffolds, cells were
seeded in the same way as for the scaffolds for SEM evaluation. Culture medium containing 30 µg/mL
fibronectin was replenished every 2 days and the samples were fixed with 4% PFA on day 3, 7 and 14.
Staining of collagen I and fibronectin was performed in the same way as described in sub-Section 4.5
Extracellular matrix production under different conditions. Eventually, the scaffolds were mounted on glass
slides using DAKO Fluorescent mounting medium and covered with glass coverslips. Z-stack images
were taken with confocal microscope (SP5, Leica Microsystems, Wetzlar, Germany) with 40x objective.
Confocal images are presented as maximum projections of the z-stacks.
4.7. Statistical Analysis
Data were analyzed with Origin (OriginPro 2017, OriginLab, Northampton, MA, USA). Values
were expressed as means ± standard deviation. For the data from the proliferation experiments,
one-way analysis of variance (one-way ANOVA) was performed to test the significance of differences
between different groups using a comparison post hoc test for significance. T-test was performed to
analyze the differences between the conditions in the gene expression experiments between groups
treated with PDGF-BB or AA, respectively, and non-treated controls. Statistical significance was
accepted for p < 0.05 marked by an asterisk (*).
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